Arbutus Biopharma Corporation ABUS Cash Flow Statement
| TTM Q1 '26 | TTM Q4 '25 | TTM Q3 '25 | TTM Q2 '25 | TTM Q1 '25 | ||
|---|---|---|---|---|---|---|
| $160.72M+310% | -$33.5M+52.1% | -$42.28M+44.9% | -$54.25M+29.6% | -$76.57M-2.9% | ||
| $44K-96.8% | $363K-73.7% | $685K-51.3% | $1.01M-29.8% | $1.36M-4.9% | ||
| $4.75M-54.9% | $6.95M-22.6% | $7.32M-19.3% | $8.22M-12.6% | $10.54M+14.7% | ||
| -$1.44M-50.2% | -$1.5M-338% | -$703K— | -$742K— | -$957K— | ||
| —— | —— | —— | -$6.62M— | $3.84M— | ||
| -$1.09M+62.0% | -$1.7M+26.1% | -$1.55M— | -$1.7M— | -$2.87M— | ||
| -$558K-20.8% | -$557K-29.5% | -$504K-9.3% | -$505K-13.0% | -$462K-4.5% | ||
| —— | —— | —— | -$11.03M-157% | -$1.93M+71.7% | ||
| -$1.92M-170% | -$1.83M-170% | $2.72M+182% | $2.79M+239% | $2.74M+11,533% | ||
| —— | —— | —— | —— | —— | ||
| -$34.36M+41.7% | -$39.64M+38.9% | -$45.27M+37.0% | -$60.19M+17.4% | -$58.95M+24.4% | ||
| $119.15M-21.0% | $140.06M-1.0% | $157.71M+28.9% | $146.74M+64.7% | $150.83M+76.0% | ||
| $125.21M-27.8% | $155.28M-5.7% | $188.13M+22.0% | $175.2M+22.2% | $173.52M+31.0% | ||
| —— | —— | —— | —— | —— | ||
| $14.42M+87.8% | $5.54M-25.9% | $5.32M-12.1% | $6.12M— | $7.68M— | ||
| $14.56M-52.0% | $5.72M-89.0% | $5.5M-89.9% | $6.43M-88.2% | $30.35M-12.4% | ||
| —— | —— | —— | —— | —— | ||
| -$13.37M— | -$18.32M— | -$9.44M— | —— | —— | ||
| $1.99M-39.8% | $2.35M-25.1% | $2.85M+0.7% | $3.29M+31.4% | $3.3M+39.6% | ||
| -$1.92M-170% | -$1.83M-170% | $2.72M+182% | $2.79M+239% | $2.74M+11,533% | ||
| —— | —— | —— | —— | —— | ||
| —— | —— | —— | -$11.03M-157% | -$1.93M+71.7% | ||
| -$1.09M+62.0% | -$1.7M+26.1% | -$1.55M— | -$1.7M— | -$2.87M— | ||
| $84K-29.4% | $95K-25.2% | $107K-24.1% | $112K-29.6% | $119K-59.5% | ||
| $1.22M-42.3% | $1.48M-34.2% | $1.74M-40.8% | $2.06M-33.2% | $2.11M-35.8% | ||
| —— | —— | —— | —— | $2.98M— | ||
| $125.21M-27.8% | $155.28M-5.7% | $188.13M+22.0% | $175.2M+22.2% | $173.52M+31.0% | ||
| —— | —— | —— | —— | —— | ||
| —— | -$39.64M+39.1% | -$45.36M+36.9% | -$60.28M+17.4% | -$59.03M+25.2% |
Chart any of these lines over time, or line them up against competitors.
Compare these in charts →Questions, answered.
- How much cash does Arbutus Biopharma Corporation generate?
- Arbutus Biopharma Corporation (ABUS) generated -$34.4M in operating cash flow over the trailing twelve months.
- Where does Arbutus Biopharma Corporation's cash flow data come from?
- Every line is extracted from Arbutus Biopharma Corporation's SEC filings (10-K and 10-Q) and tagged in XBRL. Switch between quarterly, annual, and trailing-twelve-month views, or open any line for its full history and peer comparisons.
